<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003960</url>
  </required_header>
  <id_info>
    <org_study_id>J9828 CDR0000067159</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-98032006</secondary_id>
    <secondary_id>JHOC-J9828</secondary_id>
    <secondary_id>NCI-G99-1543</secondary_id>
    <nct_id>NCT00003960</nct_id>
  </id_info>
  <brief_title>Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Bone marrow transplantation may allow the doctor to give higher
      doses of chemotherapy drugs and kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus donor
      bone marrow transplantation in treating patients who have hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the 1-year survival rate of patients with hematologic malignancies
      after treatment with HLA-matched allogeneic bone marrow transplantation after high-dose
      chemotherapy.

      OUTLINE: Patients receive oral busulfan four times a day on days -8 to -5, cyclophosphamide
      IV over 1 hour on days -4 to -1, and methylprednisolone IV over 1 hour every 12 hours on days
      -2 to 0. CD34+ stem cell augmented donor bone marrow is infused on day 0. Methylprednisolone
      is administered IV over 1 hour on days 5-16, and then tapered. Patients are followed every 6
      months for 1 year and then annually thereafter.

      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">September 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of any of the following: Chronic myelogenous leukemia
        (CML) in first chronic phase Myelodysplastic syndrome Refractory anemia with excess blasts
        (RAEB) RAEB in transformation Secondary leukemias untreated or in complete remission 1
        (CR1) Acute myeloid leukemia in complete remission 2 (CR2) Acute lymphocytic leukemia (ALL)
        in CR2 High-risk acute leukemia in CR1 Ph+ ALL in CR1 or consolidation after induction
        chemotherapy Must qualify for allogeneic bone marrow transplantation (BMT) No HLA-matched,
        sibling donor for BMT available No current CNS disease No history of more than 2 episodes
        of active CNS disease

        PATIENT CHARACTERISTICS: Age: 19 to 55 Performance status: ECOG 0 or 1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL Renal:
        Creatinine no greater than 2 mg/dL Cardiovascular: LVEF at least 45% No active congestive
        heart failure, arrhythmia, or angina pectoris No myocardial infarction within the past 12
        months Pulmonary: FEV1 and FVC at least 50% predicted (75% predicted if received prior
        thoracic or mantle radiotherapy) Other: No active serious infection (e.g., mucormycosis,
        uncontrolled aspergillosis, or tuberculosis) HIV negative Not pregnant Fertile patients
        must use effective contraception No concurrent debilitating medical or psychiatric illness
        that would preclude compliance No prior malignancy except curatively treated skin cancer or
        carcinoma of the cervix

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior autologous
        or allogeneic bone marrow transplantation No prior transfusions from donor Chemotherapy:
        See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul V. O'Donnell, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Treatment and Research</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2004</study_first_posted>
  <last_update_submitted>May 1, 2014</last_update_submitted>
  <last_update_submitted_qc>May 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

